Prevention and management of postcataract cystoid macular edema

Purpose of reviewThis review highlights treatment options, both under investigation and currently available, for treating postcataract macular edema. An update on current clinical studies for postcataract macular edema has been summarized.Recent findingsPseudophakic cystoid macular edema (PCME) is a common complication of cataract surgery leading to decreased visual acuity due to inflammation promoting vascular permeability and macular edema. There is no gold standard protocol for treatment with physicians choosing topical NSAIDs and corticosteroids most commonly. Recent developments in a therapeutic approach to PCME include improved delivery methods via implantation and improved drugs and combinational therapies.SummaryWhile PCME treatments are poorly studied due to their common sudden resolution without medical intervention, chronic PCME is debilitating for patients. Clinical studies show hope for improved drug delivery methods, practices to prevent potential PCME, and improved therapeutics.